Abstract
Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). The early stage of nephropathy is manifested by the presence of low levels of urinary albumin (microalbuminuria or urinary albumin excretion ≥30 and <299 mg/day). Albuminuria is a marker for development of nephropathy in type II diabetes and for increased cardiovascular morbidity and mortality. Recent studies have demonstrated the importance of antihypertensive agents that inhibit the renin-angiotensin-aldosterone (RAA) system to reduce the risk and slow down the progression of renal disease. A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCI or benazepril HCI/hydrochlorothiazide. Other objectives include a comparison of the proportion of patients who progress to overt diabetic nephropathy and the safety of these two combination therapies in these high-risk patients.
Original language | English (US) |
---|---|
Pages (from-to) | 139-144 |
Number of pages | 6 |
Journal | Journal of Human Hypertension |
Volume | 19 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2005 |
Keywords
- ACE inhibitor
- Albuminuria
- Calcium channel blocker
- Diabetic nephropathy
- End-stage renal disease
- Microalbuminuria
ASJC Scopus subject areas
- Internal Medicine